Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.
The Rapid Response: Canada program is seed funding. Preliminary or supporting data is not required.
Goal: To provide seed funding for novel, high-risk, high-reward, translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.
Funding: A maximum of $200,000 over up to 18 months per project.
Applicant Eligibility: Eligible Principal Applicants must be working in Canada at least 30% of the time at or above the level of Postdoctoral researcher, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-Applicants/Collaborators must be at the post-doctoral level or above and can be working outside Canada.
If the Principal Applicant is not appointed at the institution from which they are applying, they need to apply with a research supervisor (an “Administrative Supervisor”) who is at or above the level of Assistant Professor or equivalent, with an appointment at the institution from which they are applying.
Applicants may appear in any role on any number of projects.
Project Eligibility: Projects must meet two conditions to be eligible:
- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool
|Alzheimer’s & Related Diseases:|
|Program opens:||September 14, 2018|
|Webinar||October 12, 2018 at 1:00pm EST. Register here.|
|LOI deadline:||December 3, 2018 at 2:00pm EST|
|Proposal deadline:||March 28, 2019 at 2:00pm EDT|
|Anticipated award notification:||May 22, 2019|